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Abstract 
Introduction: The potential effect of adipokines on the development of AF is yet to be 
established. The aim of this study was to investigate the association of baseline serum 
adipokines with 1) the presence of AF at baseline and 2) future risk of AF development. 
Material and methods: The current study is a sub-analysis of the prospective, randomised 
AVOCADO (Aspirin Vs./Or Clopidogrel in Aspirin-resistant Diabetics inflammation 
Outcomes) trial. The AVOCADO study included patients with type 2 DM burdened with at 
least two additional cardiovascular risk factors and receiving acetylsalicylic acid. In patients 
included in the current analysis adipokines and inflammatory biomarker levels were measured. 
Information on the subsequent AF diagnosis was collected after a median of 5.4 years of follow-
up.  
Results: A total of 273 patients with type 2 DM (median age 68 years; 52% male) were included 
in the initial analysis comparing patients with and without AF at baseline. Patients with 
diagnosed AF (12%) had higher levels of serum resistin (8.5 [5.8–10.5] vs. 6.9 [5.6–8.7] ng/mL; 
p = 0.034), adiponectin (6.9 [5.6–8.7] vs. 2.7 [1.8–4.2] ng/mL; p = 0.032), and N-terminal pro-
B-type natriuretic peptide (336 [148–473] vs. 108 [45–217]; p < 0.001) than non-AF patients. 
There were no significant differences in serum leptin, IL-6, and TNF-α concentrations between 
the two groups. From subjects without known AF at study entry, 19% developed AF at follow-
up. In logistic regression analysis, baseline adipokine levels did not predict AF development. 
Conclusion: In type 2 DM, patients with AF have higher resistin and adiponectin 
concentrations than patients with no AF. None of the studied adipokines proved a predictor of 
future AF development. 
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Introduction 
Atrial fibrillation (AF) is one of the most common arrhythmias, with a prevalence of 
3% among adults [1]. Due to its increasing incidence, in the coming decades we are expected 
to face a pandemic of AF. Diagnosis and treatment of AF are crucial to reduce the risk of 
thromboembolic events [2, 3]. Nowadays, the most challenging task seems to be establishing 
an AF diagnosis in asymptomatic patients. Therefore, many studies aim to assess risk factors 
of arrhythmia development and to identify subpopulations with higher risk of AF occurrence. 
Such subpopulations might benefit from a more rigorous screening for arrhythmia. 
Diabetes mellitus (DM) is a well-known risk factor of AF development [4, 5]. Moreover, 
previous studies demonstrated that DM elevates the risk of thromboembolic events in patients 
with diagnosed AF [3]. This risk remains increased even during anticoagulation therapy [6]. 
Due to similar risk factors contributing to the onset of DM and cardiovascular diseases, AF is 
diagnosed in up to 15% of patients with DM [7]. The Framingham study revealed that DM 
patients have 1.6-times (male) and 1.4-times (female) higher risk of AF, irrespective of other 
risk factors [5]. The association between DM and AF seems to be bi-directional. This complex 
relation includes ionic abnormalities, myocardium hypertrophy, and autonomic nervous system 
disturbances.     
Recent studies revealed that adipokines might play an important role in risk assessment 
in patients with diagnosed DM [8, 9]. Adipokines are involved in the regulation of insulin 
sensitivity, endothelial function, inflammatory response, and serum lipid levels [10, 11]. 
Although the association between DM and AF is well-proven, the potential effect of adipokines 
on the development of AF is yet to be established. 
The aim of this study was to investigate the association of baseline serum adipokine 
concentrations with 1) the presence of AF at baseline and 2) future risk of AF development in 
type 2 DM patients. We focused on four key adipokines: two “classic” adipokines (leptin and 
resistin) and two inflammatory cytokines released from adipose tissue (interleukin-6 [IL-6] and 
tumour necrosis factor alpha [TNF-α]). 
 
Material and methods 
Study group 
 The current study is a sub-analysis of the prospective, randomised AVOCADO (Aspirin 
Vs./Or Clopidogrel in Aspirin-resistant Diabetics inflammation Outcomes) trial. The complete 
design of the AVOCADO trial, along with its inclusion and exclusion criteria, was described 
previously [12]. In brief, the AVOCADO study included patients aged between 30 and 80 years, 
with type 2 DM, irrespective of the type of antidiabetic treatment (with the exception of diet-
only treated patients), burdened with at least two additional cardiovascular risk factors, and 
receiving 75 mg of acetylsalicylic acid (ASA) daily. Patients on anticoagulation or other 
antiplatelet regimens were excluded from the AVOCADO study. The aim of the AVOCADO 
trial was to assess the effect of an eight-week course of clopidogrel or an increased ASA dose 
(150 mg) in patients with type 2 DM and high platelet reactivity on lower ASA dose (75 mg). 
Patients who did not exhibit high platelet reactivity on ASA 75 mg daily continued this 
treatment. All laboratory assessments included in the present analysis were performed at study 
entry, i.e. before randomisation to clopidogrel or an increased ASA dose. Data on baseline 
clinical characteristics (including AF status at enrolment) were obtained during the initial visit 
in the AVOCADO study by interview, physical examination, electrocardiogram (ECG), and a 
thorough analysis of all previous medical records (including previous ECGs and Holter-ECGs, 
if available). 
 The current study included only those participants of the AVOCADO trial for whom 
information on baseline AF status as well as measurements of baseline leptin, resistin, IL-6, 
and TNF-α concentrations were available. These patients were divided into two groups: 1) 
patients with known paroxysmal, persistent, or permanent AF at baseline and 2) patients with 
no known AF at enrolment. These two groups were compared with respect to clinical and 
laboratory characteristics (including adipokine levels). 
 After a median of 5.4 years, patients with no known AF at study entry were contacted 
by telephone, and information on the diagnosis of AF at follow-up was collected. During the 
telephone call, a thorough analysis of the patient’s medical documentation and current 
pharmacotherapy was carried out in order to establish a credible diagnosis of AF. Data on 
survival were obtained from the National ID Number Database. Patients who died during 
follow-up were excluded from the final analysis.  
The AVOCADO study protocol was accepted by the Local Ethical Review Board, and 
every patient signed an informed consent form to participate in the study.  
 
Laboratory assessments 
All laboratory parameters were measured in blood samples collected from all subjects 
in the morning after overnight fasting during an outpatient visit. Haematology and biochemical 
parameters were measured, including complete blood count, ions, creatinine, lipid profile, 
glucose, glycated haemoglobin, and high-sensitivity C-reactive protein (CRP). 
Additionally, in all patients included in the current analysis, leptin, resistin, IL-6, and 
TNF-α levels were assessed. All serum samples were stored at a temperature of –80°C before 
the laboratory assessment. The following kits were used for evaluation of adipokine levels: 
Human Leptin Quantikine ELISA Kit® (R&D Systems Inc., Minneapolis, Minnesota, United 
States), Human Resistin Quantikine ELISA Kit® (R&D Systems Inc.), Quantikine HS ELISA 
Human TNF-α Immunoassay® (R&D Systems Inc.), and Quantikine HS ELISA Human IL-6 
Immunoassay® (R&D Systems Inc.). The baseline high-molecular weight (HMW) adiponectin 
concentration was assessed for 190 patients using Human HMW Adiponectin Quantikine 
ELISA Kit ® (R&D Systems Inc.).  
 
Study endpoint 
 The study endpoint was AF diagnosed during the follow-up period. Only an AF 
diagnosis confirmed by the patient’s medical documentation was considered as an endpoint.  
 
Statistical analysis 
 All categorical and continuous variables were presented as percentages and median 
values with interquartile ranges (IQR), respectively. Continuous variables were non-normally 
distributed, which was calculated with the Shapiro-Wilk test. Differences between subgroups 
were assessed with Fisher’s exact test and the Mann-Whitney U test, respectively, for 
categorical and continuous variables. Univariate logistic regression was used to identify 
predictors of AF onset.  A multivariate logistic regression model was developed including risk 
factors with p < 0.1 in univariate logistic regression. Tests were considered significant for p-
values < 0.05. Statistical analysis was calculated using SAS® software, version 9.4. 
 
Results 
 A total of 273 patients with type 2 DM (median age: 68 years, IQR: 61–74 years, 52% 
male) were included in the initial analysis comparing patients with and without AF at baseline. 
Complete follow-up for subjects without known AF at study entry, with a median duration of 
5.4 years (IQR 4.8–5.9 years), was obtained for 171 patients. A flowchart of patient selection 
in the present analysis is shown in Figure 1. 
 
Comparison of patients with and without AF at baseline  
 At study entry, 30 patients (11%) had known AF. Comparison between patients with 
and without AF at study entry revealed higher levels of serum resistin, adiponectin, and N-
terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with diagnosed AF. A trend 
towards higher serum level of IL-6 was noted in patients with AF. There was no difference in 
serum leptin and TNF-α concentrations between the two groups. We observed higher 
prevalence of heart failure and a trend towards older age in patients with diagnosed AF 
compared to patients without AF. Baseline characteristics of analysed groups are presented in 
Table 1.  
 
Predictors of AF development at follow-up 
 Out of 171 patients with no AF at baseline and a complete follow-up, AF was diagnosed 
in 33 (19%) patients. In univariate analysis, baseline adipokine levels did not predict AF 
development. We observed higher risk of AF onset in patients with a history of myocardial 
infarction. There were trends towards a higher risk of AF onset in patients with higher NT-
proBNP concentration, a history of ischaemic heart disease, and longer DM history (Tab. II). 
In multivariate logistic regression analysis, only a history of myocardial infarction proved an 
independent risk factor of AF development (Tab. III). 
 
Discussion 
 In the studied group of type 2 DM patients, serum concentrations of adipokines were 
not associated with future AF development. However, patients with a diagnosis of AF at 
baseline had higher serum levels of resistin and adiponectin, and a trend towards higher IL-6 
concentration compared with patients without known AF. 
 
Baseline adipokine levels and future atrial fibrillation development  
In contrast to our study, Ermakov at al. revealed that in a group of postmenopausal women 
(50–79 years-old), during over 11 years of observation, serum resistin levels were 
independently associated with new AF onset [13]. The authors concluded that resistin may be 
considered as a biomarker that partially mediates the relationship between obesity and AF. 
Notably, the incidence of new AF onset in the group of postmenopausal women was similar to 
that seen in our study (18.1% vs. 19.3%, respectively), but the duration of follow-up was twice 
as long. This shows that DM and other cardiovascular diseases requiring antiplatelet treatment 
(present in our study group) should be considered strong risk factors of AF development. So 
far, there are no data on resistin or its receptors as potential targets for intervention to reduce 
the incidence of AF. 
Similar results were presented in a sub-analysis of the Framingham study [14]. During a 
follow-up of 7.6 ± 2.0 years new AF development was observed in 8.3% of patients. However, 
the effect of resistin lost significance after adjustment for CRP. The authors did not observe any 
relationship between serum adiponectin level and the risk of AF development. 
The potential role of resistin in the pathophysiology of AF is not clear. Resistin is associated 
with other risk factors of AF, such as DM and coronary artery disease, but in the presented 
studies the effect of resistin on AF onset was observed even after adjustment for traditional risk 
factors of AF development. High serum resistin level may reflect increased systemic 
inflammatory response. Previous studies revealed strong correlation between resistin and CRP, 
IL-6, and TNF-α levels. Secretion of all these substances is regulated by nuclear factor-κB 
pathway [15]. Resistin is also related to reduced contractility and hypertrophy of 
cardiomyocytes [16]. Moreover, resistin is an independent risk factor of unfavourable outcome 
in patients with type 2 DM [17]. 
The effect of adiponectin and leptin on AF development has not yet been established. The 
study of Ermakov et. al, cited above, revealed no relationship between serum leptin level and 
AF development. A different study showed a strong relationship between serum leptin 
concentration and risk of heart failure and other cardiovascular diseases [18]. However, this 
effect was attenuated after adjustment for body mass index. In an animal model, leptin was 
involved in cardiac fibrosis [19]. This effect was not fully proven in humans. The lack of 
relationship between serum adiponectin level and new AF onset in our study contrasts with that 
of Ermakov et al. [13]. In the whole cohort, no effect of adiponectin level on AF development 
was noted. However, in a subgroup of patients with treated DM, adiponectin was a strong 
predictor of subsequent AF diagnosis. Patients in the fourth quartile of serum adiponectin levels 
had an over six-fold higher risk of AF development compared with patients in the first quartile. 
Similarly, Macheret et al. revealed that in a group of 2376 elderly patients (mean age: 74 ± 5 
years) with no chronic cardiovascular disease, higher serum adiponectin level was related to an 
increased risk of new AF [20]. The presented relationship contrasts with the well-described 
protective role of adiponectin, which is considered an anti-inflammatory and insulin-sensitising 
hormone [21]. This adiponectin “paradox” might be explained by possible adiponectin 
resistance and related to higher serum adiponectin level in older patients and in patients with 
diagnosed cardiovascular diseases [22, 23]. 
 
Other risk factors of atrial fibrillation development 
 The association of prior myocardial infarction with subsequent AF development, 
observed in our study, was also shown in other studies. In the analysis of 4764 Framingham 
Heart Study participants, after adjustment for age and gender, myocardial infarction was 
associated with an almost 1.5-fold higher risk of new AF onset [24]. This relationship seems to 
be complex and may be partially explained by a more intense inflammatory response and a 
higher risk of heart failure in patients with a history of myocardial infarction [25]. 
 
Adipokine levels in patients with a current diagnosis of atrial fibrillation 
 Despite no effect of analysed adipokines on future AF development, our study showed 
higher serum levels of resistin and adiponectin in patients with diagnosed AF compared with 
non-AF patients. In a study by Özcan et al., when compared with a control group matched for 
demographics and clinical characteristics, patients with AF had higher serum resistin levels 
[26]. In the AF group, higher serum levels of CRP were also observed. These results suggest a 
relationship between resistin and systemic inflammatory response. Another study showed 
higher serum adiponectin levels in patients with persistent AF compared with patients with 
paroxysmal AF and a control group [27]. This relationship might be explained by 
hyposensitivity of adiponectin receptors in AF patients and higher secretion of adiponectin in 
this group. In a study by Kim et al., higher serum adiponectin level was associated with 
recurrences of AF after pulmonary vein isolation [28]. This observation implies unfavourable 
atrial remodelling in patients with higher adiponectin levels. In our study, we observed a trend 
towards higher serum levels of IL-6 in patients with AF compared to patients without AF. This 
finding confirms the role of inflammation in the pathogenesis of AF. Similarly, Marcus et al. 
analysed a group of patients with coronary artery disease and showed elevated levels of IL-6 in 
patients with AF compared to patients without AF [29]. Interestingly, no association between 
CRP and AF was found. This observation proved that inflammation affects AF development 
via a CRP-independent pathway. In our analysis, we did not observe differences in the levels 
of CRP or TNF-α between patients with and without AF. However, a previous study showed 
that higher TNF-α may be related to larger left atrium and involved in AF development [30]. In 
an animal model, TNF-α was associated with atrial fibrosis mainly through the influence on 
TNF-β signalling pathway [31]. 
 
Study group considerations 
 One of the exclusion criteria in the AVOCADO study was anticoagulation therapy. This 
decreased the number of patients with AF at baseline in the studied population. Nonetheless, at 
the time of patient recruitment to the AVOCADO study, ASA was approved for stroke 
prevention in moderate-risk patients (i.e. with 1 point in the CHADS2 score) or in patients with 
contraindications to oral anticoagulation [32]. In an observational study, including over 17,000 
DM patients aged between 65 and 74 years old, Nichols et al. reported AF with a prevalence of 
7% [33]. Baseline AF prevalence in our study was 11%. Importantly, despite differences in 
resistin and adiponectin concentrations, we observed comparable values of body mass index 
and waist-hip ratio in patients with and without AF at baseline.  
 
Study limitations 
 An important limitation of our analysis is that the AVOCADO study was primarily 
designed to assess laboratory response to antiplatelet treatment, which affected baseline 
characteristics of the study population. Secondly, the analysed group was quite heterogenous, 
with an interquartile range of DM duration ranging from 3 to 15 years, and with a wide spectrum 
of antidiabetic and cardiovascular pharmacological regimens. Furthermore, a larger study group 
and a longer follow-up might have revealed possible associations between adipokine levels and 
the risk of subsequent AF development. Almost 17% of patients were lost to follow-up. Finally, 
our analysis was based on a currently known diagnosis of AF (and in follow-up, this information 
was obtained from the patients via telephone). No additional tests, such as Holter ECG 
monitoring, were used to detect asymptomatic AF episodes. This might have resulted in a false 
classification of some patients with silent AF as non-AF patients.  
 
Conclusion 
In type 2 DM, patients with AF have higher resistin and adiponectin concentrations than 
patients with no AF. Among patients with no AF at baseline who survived to follow-up, one in 
five developed AF at five years. In this group, none of the studied adipokines proved to be a 
predictor of future AF development.  
 
Key messages 
Patients with a diagnosis of atrial fibrillation (AF) at baseline had higher serum levels of resistin 
and adiponectin compared with patients without known AF. 
 
In the studied group of type 2 diabetes mellitus patients, serum concentrations of adipokines 
were not associated with future AF development 
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Figure 1. Flowchart of subgroups selection. AF — atrial fibrillation; DM — diabetes mellitus; 
pts — patients 
 Table I. Baseline characteristics of patients with and without atrial fibrillation (AF) at study 
entry 
 
Total (n = 
273) 
No AF at 
baseline (n = 
243) 
AF at 
baseline (n = 
30) 
p-value 
Demographics 
Age [years] 68 (61–74) 68 (60–74) 71 (64–76) 0.08 
Male 52% 52% 53% 1.00 
Clinical assessment 
Body mass index [kg/m2] 
30.3 (27.1–
33.1) 
30.3 (27.1–
33.1) 
30.2 (26.8–
33.0) 
0.73 
Waist–hip ratio 
0.97 (0.91–
1.03) 
0.97 (0.91–
1.03) 
0.96 (0.90–
1.01) 
0.38 
Systolic blood pressure [mmHg] 
140 (130–
150) 
140 (130–
150) 
138 (120–
155) 
0.29 
Diastolic blood pressure 
[mmHg] 
80 (70–86) 80 (70–86) 80 (70–86) 0.43 
Heart rate [beats/min] 70 (65–78) 72 (65–79) 70 (64–71) 0.053 
Medical history 
Diabetes mellitus duration 
[years] 
8 (3–15) 8 (3–15) 6 (2–14) 0.24 
Diabetes mellitus treated with 
oral antidiabetic drugs 
86% 86% 90.0% 0.80 
Metformin 61% 62% 50.5% 0.24 
Diabetes mellitus treated with 
insulin 
29% 30% 20.0% 0.29 
Hypertension 93% 93% 93% 1.00 
Ischaemic heart disease 55% 55% 53% 0.85 
Dyslipidaemia 82% 83% 73% 0.21 
Prior myocardial infarction 30% 30% 37% 0.53 
Chronic heart failure 37% 35% 55% 0.042 
Prior ischaemic stroke 7.0% 6.6% 10% 0.45 
History of smoking 57% 58% 53% 0.70 
Laboratory findings 
White blood cells [1000/mcL] 6.7 (5.7–7.8) 6.7 (5.8–7.7) 6.8 (5.4–9.3) 0.66 
Haemoglobin [g/dL] 
13.9 (13.0–
14.7) 
13.9 (13.0–
14.8) 
14.0 (13.1–
14.4) 
0.87 
Estimated glomerular filtration 
rate [ml/min/1.73 m2] 
69.2 (56.6–
83.7) 
69.5 (56.7–
84.9) 
65.6 (54.8–
77.3) 
0.37 
Sodium [mmol/L] 
141.2 
(139.1–
142.9) 
141.1 
(138.8–
142.9) 
142.1 
(140.3–
142.9) 
0.07 
Potassium [mmol/L]  4.5 (4.2–4.7) 4.4 (4.2–4.7) 4.5 (4.2–4.6) 0.95 
Total cholesterol [mg/dL] 
160 (139–
186) 
161 (140–
186) 
158 (134–
198) 
0.75 
Low-density lipoprotein 
[mg/dL] 
85 (65–107) 85 (66–106) 79 (63–116) 0.94 
High-density lipoprotein 
[mg/dL] 
47 (39–56) 47 (39–56) 46 (40–57) 1.00 
Triglycerides [mg/dL] 123 (91–164) 124 (92–165) 114 (89–153) 0.48 
Glycated haemoglobin (%) 6.6 (6.1–7.6) 6.7 (6.2–7.7) 6.4 (5.7–7.1) 0.018 
Leptin [ng/mL] 
18.0 (9.4–
32.4) 
18.0 (9.4–
32.4) 
18.8 (7.8–
36.0) 
0.93 
Resistin [ng/mL] 
7.0 (5.6–9.0) 6.9 (5.6–8.7) 8.5 (5.8–
10.5) 
0.034 
Adiponectin [ng/mL] 
2.9 (1.9–4.4) 
[n = 190] 
2.7 (1.8–4.2) 
[n = 167] 
3.6 (2.7–6.0) 
[n = 23] 
0.032 
Tumour necrosis factor alpha 
[pg/mL] 
1.8 (1.2–2.3) 1.8 (1.2–2.3) 2.0 (1.3–2.5) 0.39 
Interleukin-6 [pg/mL] 2.4 (1.5–4.2) 2.3 (1.5–4.0) 3.3 (1.6–5.4) 0.09 
High sensitivity C-reactive 
protein [mg/L] 
2.6 (1.4–4.5) 2.6 (1.5–4.5) 3.1 (1.3–5.0) 0.74 
N-terminal pro-B-type 
natriuretic peptide [pg/mL] 
117 (53–252) 108 (45–217) 336 (148–
473) 
< 0.001 
Concomitant medications 
Beta-blockers 73% 71% 86% 0.12 
Angiotensin-converting enzyme 
inhibitors 
66% 67% 52% 0.10 
Calcium channel blockers 39% 41% 24% 0.10 
Nitrates 5.9% 5.0% 14% 0.08 
Loop diuretics 17% 16% 32% 0.038 
Thiazide diuretics 7.4% 7.0% 10% 0.46 
Indapamide 29% 30% 17% 0.19 
Mineralocorticoid receptor 
antagonists 
5.9% 5.8% 6.9% 0.68 
Angiotensin receptor blockers 20% 19% 28% 0.32 
Statins 73% 74% 73% 1.00 
Fenofibrate 13% 13% 14% 1.00 
Digoxin 1.5% 0.8% 6.9% 0.06 
 
  
Table II. Univariate logistic regression analysis of predictors of atrial fibrillation development 
at follow-up 
 OR (95% CI) p-value 
Demographics 
Age [per 10 years] 1.07 (0.69–1.67) 0.759 
Male  0.89 (0.42–1.90) 0.760 
Clinical assessment 
Body mass index [per kg/m2] 1.02 (0.94–1.11) 0.618 
Waist-hip ratio [per 0.1] 1.31 (0.87–1.97) 0.198 
Systolic blood pressure [per 10 mmHg] 0.91 (0.74–1.11) 0.346 
Diastolic blood pressure [per 10 mmHg] 0.79 (0.57–1.10) 0.162 
Heart rate [per 10 beats/min] 0.77 (0.52–1.15) 0.203 
Medical history 
Diabetes mellitus duration [per 10 years] 1.44 (0.98–2.12) 0.065 
Diabetes mellitus treated with oral 
antidiabetic drugs 
0.47 (0.16–1.34) 0.158 
Diabetes mellitus treated with insulin 1.14 (0.50–2.63) 0.751 
Hypertension 0.79 (0.21–3.06) 0.737 
Ischaemic heart disease 2.00 (0.90–4.44) 0.089 
Dyslipidaemia 0.50 (0.20–1.23) 0.144 
Prior myocardial infarction 3.52 (1.60–7.75) 0.002 
Chronic heart failure 1.56 (0.72–3.43) 0.253 
Prior ischaemic stroke 1.28 (0.33–4.94) 0.720 
History of smoking 1.12 (0.51–2.42) 0.783 
Laboratory findings 
White blood cells [per 1000/mcL] 1.11 (0.92–1.35) 0.281 
Haemoglobin [per g/dL] 0.81 (0.61–1.09) 0.162 
Estimated glomerular filtration rate [per 
10 ml/min/1.73 m2] 
1.03 (0.86–1.22) 0.786 
Sodium [per mmol/L] 0.89 (0.78–1.03) 0.108 
Potassium [per mmol/L]  0.60 (0.24–1.48) 0.268 
Total cholesterol [per 10 mg/dL] 0.96 (0.86–1.07) 0.477 
Low-density lipoprotein [per 10 mg/dL] 0.97 (0.85–1.11) 0.668 
High-density lipoprotein [per 10 mg/dL] 0.89 (0.66–1.20) 0.441 
Triglycerides [per 10 mg/dL] 1.03 (0.97–1.08) 0.322 
Glycated haemoglobin [per %] 1.20 (0.91–1.59) 0.201 
Leptin [per ng/mL] 0.99 (0.97–1.02) 0.535 
Resistin [per ng/mL] 1.07 (0.96–1.20) 0.199 
Adiponectin [ng/mL] 0.94 (0.74–1.12) 0.597 
Tumour necrosis factor alpha [per 0.1 
pg/mL] 
1.02 (0.99–1.05) 0.160 
Interleukin-6 [per 0.1 pg/mL] 1.01 (0.99–1.02) 0.224 
High sensitivity C-reactive protein [per 
mg/L] 
1.03 (0.98–1.09) 0.228 
N-terminal pro-B-type natriuretic peptide 
[per 100 pg/mL] 
1.10 (0.99–1.22) 0.077 
OR — odds ratio; CI — confidence interval 
Table III. Multivariate logistic regression analysis of predictors of atrial fibrillation 
development at follow-up 
 OR (95% CI) p-value 
Diabetes mellitus duration [per year] 1.02 (0.98–1.06) 0.342 
Ischaemic heart disease  1.06 (0.38–2.94) 0.911 
Prior myocardial infarction 3.11 (1.16–8.34) 0.025 
N-terminal pro-B-type natriuretic peptide 
[per 100 pg/mL] 
1.08 (0.92–1.33) 0.158 
CI — confidence interval 
